Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.

American journal of clinical oncology - 1 Apr 2014

Cubillo Antonio, Hernando-Requejo Ovidio, García-García Elena, Rodriguez-Pascual Jesús, De Vicente Emilio, Morelli Pía, Rubio Carmen, López-Ríos Fernando, Muro Avertano, López Ulpiano, Prados Susana, Quijano Yolanda, Hidalgo Manuel

Abstract excerpt

PURPOSE: To investigate the feasibility of personalizing chemotherapy in patients with rectal cancer. METHODS: Patients with cT3 or cN1 and cM0 rectal cancer were eligible. A set of 6 molecular markers including KRAS, BRAF, and PI3K mutations and expression of topoisomerase-1 (Topo-1), ERCC-1, and thymidylate synthase (TS) using immunohistochemistry were performed in a tumor biopsy. All patients were treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Deoxycytidine

Share to DNA Topoisomerases, Type I

Share to Irinotecan

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Identifiers

PMID: 23211222
DOI: 10.1097/COC.0b013e31826e0703

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.PMID 23211222Read ↗

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.Semantic proximity Read ↗

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.Semantic proximity Read ↗

Assessing the practice of Total Neoadjuvant Therapy for rectal cancer: an online survey among Radiation Oncology Departments in Germany and German-Speaking Regions of Austria and SwitzerlandSemantic proximity Read ↗

Genomic-adjusted radiation dose and outcomes in radiotherapy-treated locally advanced rectal cancer: a pooled multicohort analysis including the TIMING, OPRA, and CAO/ARO/AIO-94 prospective trialsSemantic proximity Read ↗

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Semantic proximity Read ↗

Modeling rectal cancer to advance neoadjuvant precision therapy.Semantic proximity Read ↗

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).Semantic proximity Read ↗

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.Semantic proximity Read ↗

X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.Semantic proximity Read ↗

Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.